This message was sent to ##Email##
|
|
|
|
|
| |
The JAMA Network
Greater incorporation of numerical metastatic nodal burden into nodal classification for hypopharyngeal and laryngeal cancers may streamline staging, refine patient prognosis and triage patients who may benefit from adjuvant treatment. Nodal staging for laryngohypopharyngeal cancers is based primarily on size and laterality, with less value placed on absolute number of metastatic lymph nodes (LNs). We are aware of no studies to date that have specifically addressed the prognostic effect of quantitative nodal burden in larynx or hypopharynx malignancies.
READ MORE
ACS Quality Programs
The 2018 ACS Quality and Safety Conference: Partners in Quality will be held in Orlando, July 21-24. This education program brings health care professionals together to discuss and apply current knowledge pertaining to national and local quality initiatives in the field of surgery. Attendees will learn techniques to manage, analyze and interpret data to make a positive impact at their facilities. The Cancer Programs are excited to be included in this one-of-a-kind conference and encourage staff working in CoC — and/or NAPBC-accredited programs to submit an abstract for a podium or poster presentation. The abstract should relate to surgical quality improvement initiatives, including the development, implementation or validation of best practices within your accredited program. Abstracts for this conference will be accepted until Jan. 26, 2018. (Please note: This is not the 2018 Cancer Program Annual Conference that will be held in the fall of 2018. Information on the 2018 Cancer Programs Annual Conference will be available in early January 2018.)
READ MORE
The Medical News
The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2). Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer and the second biosimilar approved in the U.S. for the treatment of cancer.
READ MORE
The Medical News
Researchers at NYU Langone Health's Perlmutter Cancer Center report that at least three kinds of bacteria in the mouths of Americans may heighten or lower their risk of developing esophageal cancer.
Publishing online in the journal Cancer Research, an analysis of data from two national studies involving more than 120,000 patients finds a 21 percent increased cancer risk tied to the presence of Tannerella forsythia, bacteria commonly linked to gum disease.
READ MORE
|
Promoted by
|
|
|
|
 |
ACS-AJCC
Register now for the live AJCC Staging Manual Eighth Edition for registrars on Introduction & Descriptors, which will provide information to demonstrate purpose and approach to AJCC staging, outline use of stage descriptors and guidelines and dissect the 8th edition one-page guide. Future webinars are scheduled as follows: Feb. 15, 2018 - Minor Rule Changes; March 20, 2018 - Major Rule Changes; April 17, 2018 - CAnswer Forum & Staging Questions; July 25, 2018 - Head and Neck Staging; Sept. 6, 2018 -Breast Staging. All webinars will be held from 1:00-2:00 p.m. CT. Make sure to mark your calendars. Additional information and registration links coming soon. Earn free Category A CE credits for the live or recorded webinars. Visit the AJCC website for updates.
Massachusetts Eye and Ear Infirmary via Medical Xpress
Head and neck tumors that contain cells undergoing a partial epithelial-to-mesenchymal transition — which transforms them from neatly organized blocks into irregular structures that extrude into the surrounding environment — are more likely to invade and spread to other parts of the body, according to a new study led by researchers from Massachusetts .
READ MORE
PLOS via ScienceDaily
A given gene may perform a different function in breast cancer cells than in healthy cells due to changes in networks of interacting proteins, according to a new study published in PLOS Computational Biology. Previous research has shown that a protein produced by a single gene can potentially have different functions in a cell depending on the proteins with which it interacts. Protein interactions can differ depending on context, such as in different tissues or developmental stages.
READ MORE
| |
PRODUCT SHOWCASE | Advertisement
|
 |
|
Enjoy our journals? There’s an app for those! Journals such as those from the American Cancer Society ™, Journal of Surgical Oncology, Cancer Science and more are now available for your iPad and iPhone. Sample issues and abstracts, as well as open articles, can be accessed for free. A subscription to the journal is required to read the full text. Click here to learn more!
|
|
ACS
To hear an update from Dr. Richard Wender on the 80% by 2018 initiative and the incredible progress made and to learn more about the American Cancer Society's plans for the campaign moving forward, watch the webinar replay or check out Beyond 2018 FAQ.
American Journal of Preventive Medicine via Medical Xpress
A new study suggests that an American Cancer Society (ACS) program has been effective in promoting improvements in colorectal cancer screening rates in federally qualified health centers (FQHCs). The study appears early online in the American Journal of Preventive Medicine, and the authors say it has implications for broader public health efforts to increase cancer prevention and screening.
READ MORE
Healio
The FDA approved a next-generation sequencing-based in vitro diagnostic test that can detect genetic mutations in 324 genes and two genomic signatures in any solid tumor. The FDA has approved other companion diagnostics that match one test to one drug.
FoundationOne CDX (Foundation Medicine Inc.) is designed to be a more extensive test that provides information about several genetic mutations that may help guide treatment of patients with cancer.
READ MORE
 |
|
Novodiax is soon bringing to market 10-minute fast, sensitive and simple Immunoassay (IHC) kits for in vitro diagnostic use to address unmet needs in the intraoperative surgical oncology sector. Learn More
|
|
Johns Hopkins University School of Medicine via Medical Xpress
Johns Hopkins Kimmel Cancer Center researchers and colleagues have identified a novel drug combination therapy that could prime nonsmall cell lung cancers to respond better to immunotherapy. These so-called epigenetic therapy drugs, used together, achieved robust anti-tumor responses in human cancer cell lines and mice.
READ MORE
Cold Spring Harbor Laboratory via ScienceDaily
The facts about prostate cancer can be confusing. It's the third most common cancer type among Americans — 161,000 men will be diagnosed this year, the National Cancer Institute (NCI) estimates. Yet according to the NCI, 98.6 percent will be alive in 5 years. While it's often not lethal, prostate cancer still kills lots of men — 21,000 this year — because it's so common. Many of its victims have metastatic disease at the time of diagnosis — their cancer has already spread. Can we catch potentially lethal cancers earlier to save some of these men?
READ MORE
 |
|
Doctors Without Borders/Médecins Sans Frontières (MSF) is actively recruiting general and trauma surgeons with experience in emergency obstetrics for international missions in developing countries. Learn more.
|
|
| | IMPORTANT AND DEADLINE DATES |
|
Missed last week's issue? See which articles your colleagues read most.
|
Don't be left behind. Click here to see what else you missed.
|
|
|
|
The Brief
Connect with AJCC
Connect with CoC
Connect with NAPBC
Recent Issues | Subscribe | Unsubscribe | Advertise | Web Version
Colby Horton, Vice President of Publishing, 469-420-2601 | Download media kit
Ashley Harrington, Senior Content Editor, 469-420-2642 | Contribute news
Disclaimer: The Brief is a digest of news selected for the Commission on Cancer (CoC) and the National Accreditation Program for Breast Centers (NAPBC), both quality programs of the American College of Surgeons, from thousands of sources by the editors of MultiBriefs, an independent organization that also manages and sells advertising. The CoC and NAPBC do not endorse any of the advertised products and services. Opinions expressed in the articles are those of the author and not of the American College of Surgeons, the CoC and the NAPBC.
American College of Surgeons
633 N Saint Clair Street | Chicago, IL, 60611-3211 | 800-621-4111 | Contact Us
Learn how to add us to your safe sender list so our emails get to your inbox. |
|
| |
|
|
7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063
|
